{"nctId":"NCT05073315","briefTitle":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","startDateStruct":{"date":"2021-10-04","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":425,"armGroups":[{"label":"Continued-use Group (Adalimumab)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Adalimumab"]},{"label":"Switching Group (Adalimumab - ABP 501)","type":"EXPERIMENTAL","interventionNames":["Drug: Adalimumab","Drug: ABP 501"]}],"interventions":[{"name":"Adalimumab","otherNames":["Humira®"]},{"name":"ABP 501","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants has moderate to severe plaque psoriasis (with or without psoriatic arthritis) for at least 6 months and has stable disease for at least 2 months\n* Participants has a score of PASI ≥ 12, involvement of ≥ 10% body surface area (BSA) and static Physician's Global Assessment (sPGA) ≥ 3 at screening and at baseline\n* Participant has no known history of latent or active tuberculosis\n\nExclusion Criteria:\n\n* Participant has erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication induced psoriasis, or other skin conditions at the time of screening (eg, eczema) that would interfere with evaluations of the effect of investigational product of psoriasis\n* Participant has an active infection or history of infections\n* Participant has received biologic treatment for psoriasis within the previous month or 5 drug half-lives (whichever is longer) prior to enrollment\n* Participant has received nonbiologic systemic psoriasis therapy within 4 weeks prior to enrollment\n* Participant has received ultraviolet (UV) A phototherapy (with or without psoralen) or excimer laser within 4 weeks prior to enrollment, or UV B phototherapy within 2 weeks prior to enrollment\n* Participant has received topical psoriasis treatment within 2 weeks prior to enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)","description":"Participants analyzed according to actual treatment received.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1458.03","spread":"156.6"},{"groupId":"OG001","value":"1472.68","spread":"174.9"}]}]}]},{"type":"PRIMARY","title":"Maximum Serum Concentration (Cmax) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)","description":"Participants analyzed according to treatment received.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":"153.6"},{"groupId":"OG001","value":"5.01","spread":"160.4"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Maximum Serum Concentration (Tmax) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)","description":"Time to reach maximum serum concentration.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.30","spread":null},{"groupId":"OG001","value":"72.35","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Concentration (Ctrough) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4528.7316","spread":"88.9"},{"groupId":"OG001","value":"4072.5556","spread":"119.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4046.3069","spread":"144.1"},{"groupId":"OG001","value":"3682.0016","spread":"188.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4113.0839","spread":"160.8"},{"groupId":"OG001","value":"4332.1272","spread":"148.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3736.9917","spread":"182.1"},{"groupId":"OG001","value":"4014.4980","spread":"193.5"}]}]}]},{"type":"SECONDARY","title":"PASI Percent Improvement From Baseline (Day 1) to Week 30","description":"The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.\n\nPercent improvement from baseline was calculated as (value at baseline - value at post-baseline visit) × 100 / (value at baseline).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.56","spread":null},{"groupId":"OG001","value":"91.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving PASI 75 Response at Week 30","description":"A PASI 75 response is a 75% or greater improvement (reduction) from baseline in PASI score. The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving PASI 90 Response at Week 30","description":"A PASI 90 response is a 90% or greater improvement (reduction) from baseline in PASI score. The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving PASI 100 Response at Week 30","description":"A PASI 100 response is a 100% or greater improvement (reduction) from baseline in PASI score. The PASI measures the average redness (erythema), thickness (induration), and scaliness (each graded on a 0 to 4 scale) of psoriasis lesions, weighted by the area of involvement in the four main body areas (i.e., head and neck, trunk, upper extremities, and lower extremities). PASI scores can range from 0.0 to 72.0, with higher scores indicating greater severity and/or more extensive psoriasis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Treatment-emergent Adverse Events (TEAE)","description":"TEAEs are any event that occurred after the participant received study treatment. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests that occurred after study treatment administration were recorded as TEAEs.\n\nA serious TEAE is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment(s) that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Events of Interest (EOI)","description":"An EOI is defined as a noteworthy event for a particular product or class of products that a sponsor may wish to monitor carefully. It could be serious or non-serious and could include events that might be potential precursors or prodromes for more serious medical conditions in susceptible individuals.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-drug Antibodies (ADA) Expression Post Randomization","description":"Anti-drug antibody samples were drawn prior to investigational product administration at dosing visits.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null},{"groupId":"OG001","value":"194","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"182","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":425},"commonTop":["Nasopharyngitis","COVID-19","Headache"]}}}